Andere talen Vistagen Therapeutics, Inc.

Aandelen

VTGN

US92840H4002

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,37 ^USD	-2,46%		-2,89%	-14,98%

25/04	Vistagen kondigt positieve resultaten aan van een Fase 2A pilotstudie van Ph15 voor verbetering van psychomotorische stoornissen veroorzaakt door mentale vermoeidheid	CI
01/04	Vistagen start PALISADE-3 fase 3-studie met fasedienol voor de acute behandeling van sociale angststoornis na positieve resultaten van PALISADE-2	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference	07/05
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	25/04
Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	25/04
Vistagen to Present at the 2024 Anxiety and Depression Association Conference	10/04
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference	09/04
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	01/04
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	01/04
Vistagen to Present at Stifel 2024 Virtual CNS Days	11/03
Vistagen to Present at TD Cowen 44th Annual Health Care Conference	28/02
Vistagen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02
Earnings Flash (VTGN) VISTAGEN Posts Q3 Revenue $411,400	13/02
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update	13/02
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024	06/02
Vistagen to Get Patent for Neuropathic Pain Treatment Candidate in Europe	27/12
Vistagen	27/12
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	27/12
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	27/12
North American Morning Briefing : Futures Pause -2-	08/12
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Earnings Flash (VTGN) VISTAGEN Reports Q2 Revenue $277.7M	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Vistagen Therapeutics, Inc.

Aandelen

VTGN

US92840H4002

Andere talen

Filters